Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Capital Expenditures (2016 - 2023)

Avalo Therapeutics filings provide 8 years of Capital Expenditures readings, the most recent being $158000.0 for Q1 2023.

  • On a quarterly basis, Capital Expenditures changed N/A to $158000.0 in Q1 2023 year-over-year; TTM through Dec 2023 was $158000.0, a 66.32% increase, with the full-year FY2023 number at $158000.0, up 66.32% from a year prior.
  • Capital Expenditures hit $158000.0 in Q1 2023 for Avalo Therapeutics, up from $95000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $165969.0 in Q1 2019 to a low of $2.0 in Q4 2019.
  • Median Capital Expenditures over the past 5 years was $72000.0 (2020), compared with a mean of $69101.3.
  • The widest YoY moves for Capital Expenditures: up 1256.15% in 2019, down 100.0% in 2019.
  • Avalo Therapeutics' Capital Expenditures stood at $2.0 in 2019, then surged by 3149900.0% to $63000.0 in 2020, then tumbled by 82.54% to $11000.0 in 2021, then skyrocketed by 763.64% to $95000.0 in 2022, then soared by 66.32% to $158000.0 in 2023.
  • The last three reported values for Capital Expenditures were $158000.0 (Q1 2023), $95000.0 (Q3 2022), and $11000.0 (Q4 2021) per Business Quant data.